2020 Post-ESMO Report
2020 Post-ESMO Report
$4,750.00
The Annual European Society for Medical Oncology (ESMO) 2020 Congress was held virtually from September 19 to September 21, 2020 due to the COVID-19 pandemic.
Publisher: Biomedtracker
- Description
- Contents
Summary
The Annual European Society for Medical Oncology (ESMO) 2020 Congress was held virtually from September 19 to September 21, 2020 due to the COVID-19 pandemic. Conference highlights include the first numerical results for ipatasertib in prostate cancer, data from the LEAP-005 study of Lenvima +Keytruda in solid tumors, updated data from KRAS inhibitor AMG 510 in non-small cell lung cancer (NSCLC), new results from the ADAURA trial of Tecentriq in NSCLC, results from the COMBI-i trial evaluating the investigational immunotherapy spartalizumab in melanoma, and much more.
This post-meeting report features summaries of a few key topics and trends along with commentary from our analysts on specific presentations. It also includes a compilation of all data events added in conjunction with the meeting.
A full list of ESMO events is also available for download as an Excel file.
Contents
Summary ………………………………………………………………………………………………………………………….2
About the Author……………………………………………………………………………………………………………….2
Disclaimer…………………………………………………………………………………………………………………………2
Summary Figures ……………………………………………………………………………………………………………….6
Top Companies ………………………………………………………………………………………………………………………..6
Top Drugs………………………………………………………………………………………………………………………………..6
Top Indications…………………………………………………………………………………………………………………………7
Top Targets ……………………………………………………………………………………………………………………………..7
Anal Cancer ………………………………………………………………………………………………………………………8
Retifanlimab (INCY, Phase III) …………………………………………………………………………………………………….8
Breast Cancer…………………………………………………………………………………………………………………..10
Tecentriq (RHHBY, Approved)…………………………………………………………………………………………………..10
Trodelvy (IMMU, Approved)…………………………………………………………………………………………………….14
Tecentriq (RHHBY, Approved)…………………………………………………………………………………………………..17
Verzenio (LLY, Approved)…………………………………………………………………………………………………………19
Ibrance (PFE, Approved) ………………………………………………………………………………………………………….22
Cervical Cancer ………………………………………………………………………………………………………………..24
Balstilimab (AGEN, BLA)…………………………………………………………………………………………………………..24
Tisotumab Vedotin (GMAB, Phase II)…………………………………………………………………………………………25
Chemotherapy Induced Nausea and Vomiting (CINV)………………………………………………………………28
Akynzeo (Helsinn, Approved)……………………………………………………………………………………………………28
Esophageal Cancer……………………………………………………………………………………………………………30
Keytruda (MRK, Approved)………………………………………………………………………………………………………30
Opdivo (BMY, Approved) …………………………………………………………………………………………………………33
Opdivo (BMY, Approved) …………………………………………………………………………………………………………36
Gastric Cancer………………………………………………………………………………………………………………….39
Bavituximab (OncXerna, Phase II)……………………………………………………………………………………………..39
Head and Neck Cancer ………………………………………………………………………………………………………41
SNS-301 (Sensei, Phase I/II) ……………………………………………………………………………………………………..41
Bavencio (MKKGY, Phase III)…………………………………………………………………………………………………….43
Melanoma ………………………………………………………………………………………………………………………45
Lenvima (Eisai, Phase III)………………………………………………………………………………………………………….45
PDR001 (NVS, Phase III) …………………………………………………………………………………………………………..48
Merkel Cell Carcinoma ………………………………………………………………………………………………………50
Retifanlimab (INCY, Phase II) ……………………………………………………………………………………………………50
Non-Small Cell Lung Cancer………………………………………………………………………………………………..52
U3-1402 (Daiichi Sankyo, Phase I)……………………………………………………………………………………………..52
CLN-081 (Cullinan Oncology, Phase I/II) …………………………………………………………………………………….54
Tagrisso (AZN, Approved) ………………………………………………………………………………………………………..56
Libtayo (REGN, Phase III)………………………………………………………………………………………………………….59
JNJ-61186371 (JNJ, Phase I)……………………………………………………………………………………………………..64
AMG-510 (AMGN, Phase III) …………………………………………………………………………………………………….66
Keytruda (MRK, Approved)………………………………………………………………………………………………………69
Lorbrena (PFE, Approved)………………………………………………………………………………………………………..72
Lenvima (Eisai, Phase III)………………………………………………………………………………………………………….75
Ovarian Cancer ………………………………………………………………………………………………………………..76
Tecentriq (RHHBY, Phase III)…………………………………………………………………………………………………….76
Prostate Cancer ……………………………………………………………………………………………………………….79
Ipatasertib (RHHBY, Phase III)…………………………………………………………………………………………………..79
AMG 160 (AMGN, Phase I)……………………………………………………………………………………………………….82
Renal Cell Cancer ……………………………………………………………………………………………………………..84
Cabometyx / Cometriq (EXEL, Approved)…………………………………………………………………………………..84
Sarcoma …………………………………………………………………………………………………………………………86
Keytruda (MRK, Phase II) …………………………………………………………………………………………………………86
Solid Tumors……………………………………………………………………………………………………………………89
Lenvima (Eisai, Phase II)…………………………………………………………………………………………………………..89
Rubraca (CLVS, Phase II)…………………………………………………………………………………………………………..91
Lucitanib (CLVS, Phase I/II)……………………………………………………………………………………………………….92
Rebastinib (DCPH, Phase I/II)……………………………………………………………………………………………………94
Rebastinib (DCPH, Phase I/II)……………………………………………………………………………………………………96
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Biomedtracker Q4 2020 Outlook Report 
Sign up to the